

April 14, 2021

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400051

BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Scrip Symbol: RELIGARE

Scrip Code: 532915

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulations) – Religare Enterprises Limited ("REL/the Company")

Dear Sir(s),

This is in reference to our earlier submissions dated October 18, 2018, March 20, 2019, July 01, 2019 and January 30, 2020 w.r.t. the SEBI interim ex-parte Order inter-alia against Religare Finvest Limited, wholly owned material subsidiary of the Company (**RFL**) passed on October 17, 2018, read with Confirmatory Order dated March 19, 2019, modified directions dated June 28, 2019 and Securities Appellate Tribunal ("SAT") Order dated January 29, 2020 in the matter of Fortis Healthcare Limited.

In said matter, RFL has received a Show Cause Notice dated April 09, 2021 from the Securities and Exchange Board of India on April 13, 2021. RFL is taking all requisite steps in this regard.

This is for your information and record.

Thanking You,

For Religare Enterprises Limited



Reena Jayara
Company Secretary

